Education
About Us
Working with TipRanks
Follow Us
CSL (AU:CSL)
ASX:CSL
Csl362
Leukemia, Myeloid, Acute
Phase I
Completed
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
Jun 29, 2012
―
Ignextgen 10%
Idiopathic Thrombocytopenic Purpura (Itp)
Phase III
Completed
Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients
Aug 09, 2006
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does CSL (CSL) have in its pipeline
CSL is currently developing the following drugs: Csl362, Ignextgen 10%. These drug candidates are in various stages of clinical development as the company works toward FDA approval.